Oklo (NYSE: OKLO) is at the forefront of developing advanced nuclear fission power plants and nuclear fuel recycling systems. In just the past month, the stock has jumped over 115%, soaring past every projection made by Oklo’s analyst community. But is the accelerated rise in Oklo’s.... |
Good MorningEquity markets continue to hover within a tight range near record highs. The market is in wait-and-see mode, with a focus on the FOMC. The FOMC is slated to meet next week and is expected to lower interest rates and give color on the policy path in future meetings. The market expects a semi-robust pace of policy easing, with the CME FedWatch Tool forecasting 50 basis points of cuts by the year's end and another 75 to 100 bps by the end of next year.
Economic data could alter the outlook for rate cuts. Three critical reads this week, including the Q3 GDP, the PCE price index, and the non-farm payrolls report, are expected to show economic strength. With economic strength in the picture and inflation falling slowly to the 2.0% target, the FOMC need not cut as quickly as forecast. The risk is sudden economic slowing. The September JOLTs report came in at the weakest levels in years, raising fear of a recession, but remained elevated and strong relative to the pre-COVID levels, aligning with healthy economic conditions. Featured: Here’s Why Trump Won’t End The Iran War (Ad) 
| Utilities | |
Oklo (NYSE: OKLO) is at the forefront of developing advanced nuclear fission power plants and nuclear fuel recycling systems. In just the past month, the stock has jumped over 115%, soaring past every projection made by Oklo’s analyst community. But is the accelerated rise in Oklo’s... Read the Full Story |
| From Our Partners | | Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge.
Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks.
Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | | Watch Marc Chaikin's free presentation and get his full buy-and-sell list today |
| Consumer Discretionary | |
Some of the market’s biggest blue-chip stocks are not immune to offering discounts to investors; it’s not that often that participants can exploit the short-term nature of these mispricing events, so when they come along, investors need to act fast before others come in to close the ga... Read the Full Story |
| Consumer Discretionary | |
QuantumScape Co. (NYSE: QS) is a battery technology company that has been developing its next-generation solid-state lithium-metal electric vehicle (EV) battery for nearly 15 years. The auto/tires/trucks sector company is in its final stages before commercialization commences in 2025, when they ... Read the Full Story |
| From Our Partners | | Seven small gold miners - MAG Silver, Reunion Gold, Calibre Mining, Probe Gold, Rupert Resources, Loncor Gold, and G2 Goldfields - were acquired by major producers, with gains ranging from 56.6% to 1,228.6%.
Golden Portfolio's Garrett Goggin, CFA, CMT, held every one of these names before the buyouts happened. Major miners face shrinking output and record cash reserves, forcing them to acquire the small companies holding the assets they need. | | See the three gold miners Goggin expects majors to target next. |
| Consumer Discretionary | |
During earnings season, some companies will purposely release very bearish earnings reports, disclosing all the bad news at once. These are referred to as ‘kitchen sink’ quarters, where they "throw out everything but the kitchen sink." Companies will lay all their cards on the table wi... Read the Full Story |
| Finance | |
Short sellers are market bears that seek to profit from falling stock prices. Some of the more popular short sellers will put out their research reports attempting to expose a target company by implying misconduct or fraud in order to trigger investors to sell their positions. The selling action i... Read the Full Story |
| From Our Partners | | Big Tech is on pace to spend nearly $700 billion on AI infrastructure this year, and a new free report identifies five companies positioned to benefit.
One firm holds $638 billion in contracted business still to be delivered. Another saw AI chip revenue surge 143 percent, while a smaller, lesser-known player is growing revenue 93 percent by solving a key problem for expanding AI clusters. | | Get the free report before the next wave of AI earnings hits |
| Technology | |
China is the largest electric vehicle (EV) market in the world. EVs are also called new energy vehicles (NEVs) and battery electric vehicles (BEVs). However, the combination of price cuts, European Union provisional tariffs and an uncertain macroeconomic climate caused the EV industry's growth to ... Read the Full Story |
| Industrials | |
As the new financial quarter gets underway, investors should start paying attention to the different price action themes across asset classes today. While far from the ultimate gauge to predict future themes, these trends and divergences can help develop reasonable scenarios for the economy moving... Read the Full Story |
| Technology | |
The price of Onsemi (NASDAQ: ON) is down 40% from its high but won’t be for long because end-market normalization and mounting demand for its high-power semiconductor applications will collide in 2025. While the 2024 results are lackluster, the Q3 results align with the expectation growth ... Read the Full Story |
| Healthcare | |
There has been speculation of a massive merger in the medical sector between two massive health insurers. Specifically, the rumor is The Cigna Group (NYSE: CI) is interested in acquiring Humana Inc. (NYSE: HUM). The conjecture caused both stocks to react, as Cigna stock fell 10% as the rumored sur... Read the Full Story |
| Technology | |
While the clean energy theme has been reignited by the AI boom driving data centers to embark on nuclear energy, solar energy stocks have been taken to the woodshed. Despite favorable long-term growth prospects, the weakness in the industry can be attributed to a number of factors, including high ... Read the Full Story |
| Wednesday's Early Bird Stock Of The Day Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana. | Should I Buy Eli Lilly and Company Stock? LLY Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Eli Lilly and Company was last updated on Sunday, August 30, 2026 at 6:03 PM.
Eli Lilly and Company Bull Case -
The company recently reported earnings per share (EPS) of $8.38, significantly exceeding analysts' expectations, indicating strong financial performance.
-
Eli Lilly and Co has a robust net margin of over 33%, suggesting efficient management and profitability, which can lead to higher returns for investors.
-
The stock has shown impressive revenue growth, with a year-over-year increase of nearly 48%, reflecting strong demand for its products.
-
The current stock price is around $1,190, which is near its twelve-month high, indicating strong market confidence in the company's future prospects.
-
The company has a solid dividend payout ratio of 23.22%, providing a steady income stream for investors through its quarterly dividends.
Eli Lilly and Company Bear Case -
The stock has a relatively high price-to-earnings (P/E) ratio of 39.23, which may suggest that it is overvalued compared to its earnings potential.
-
With a beta of 0.51, the stock is less volatile than the market, which may limit potential gains during bullish market conditions.
-
The company has a debt-to-equity ratio of 1.41, indicating a higher level of debt compared to equity, which could pose risks in economic downturns.
-
Insider selling activity has been noted, with significant shares sold recently, which may raise concerns about the company's future outlook from those closest to it.
-
The dividend yield is relatively low at 0.6%, which may not be attractive for income-focused investors compared to other investment opportunities.
| | View Today's Stock Pick |
|
| |
|
|
